Sort
16,179 grants matching “malaria”
ER-shaping proteins of Plasmodium
$650,769Purnima Bhanot · Rbhs-New Jersey Medical School · R01 · FY2022 · AI
Vanderbilt Vaccine and Treatment Evaluation Unit
$650,727Clarence Buddy Creech · Vanderbilt University Medical Center · UM1 · FY2023 · AI
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization - Service Core
$650,701Peter Skene · Seattle Children'S Hospital · U19 · FY2022 · AI
Naturally Acquired Immunity to Malaria during the Epidemiologic Transition in Ken
$650,352James Walter Kazura · Case Western Reserve University · R01 · FY2012 · AI
Targeting Hsp90 in cryptococcal fungal pathogenesis
$650,345Leah Elizabeth Cowen · University Of Toronto · R01 · FY2025 · AI
Multifidelity and multiscale modeling of the spleen function in sickle cell disease with in vitro, ex vivo and in vivo validations
$650,173George Karniadakis · Brown University · R01 · FY2022 · HL
Great Ape Reservoirs of Human Malaria
$650,124Beatrice H Hahn · University Of Pennsylvania · R01 · FY2019 · AI
Memory Regulatory T cells in Recurring Malaria
$650,020Sam Kurup · University Of Georgia · R01 · FY2025 · AI
Baseline host and environmental factors that impact pre-erythrocytic malaria vaccine (hypo)responsiveness in endemic regions
$650,010Maria Yazdanbakhsh · Leiden University Medical Center · U01 · FY2022 · AI
Baseline host and environmental factors that impact pre-erythrocytic malaria vaccine (hypo)responsiveness in endemic regions
$650,010Maria Yazdanbakhsh · Leiden University Medical Center · U01 · FY2025 · AI
Baseline host and environmental factors that impact pre-erythrocytic malaria vaccine (hypo)responsiveness in endemic regions
$650,010Maria Yazdanbakhsh · Leiden University Medical Center · U01 · FY2023 · AI
Baseline host and environmental factors that impact pre-erythrocytic malaria vaccine (hypo)responsiveness in endemic regions
$650,010Maria Yazdanbakhsh · Leiden University Medical Center · U01 · FY2024 · AI
Genomic Characterization and Surveillance of Microbial Threats in West Africa
$650,000Christian T. Happi · Redeemer'S University · U54 · FY2018 · HG
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013)
$650,000Chris Beyrer · Ias · R13 · FY2013 · AI
Task 4: Preclinical Services for the Development of Interventional Agents
$650,000Jon Carl Mirsalis · Sri International · N01 · FY2011 · AI
Epidemiology, Prevention and Treatment of Influenza and Other Respiratory Infecti
$650,000William Kwabena Ampofo · Noguchi Memorial Institute / Medical Res · U01 · FY2013 · IP
Predicting neurodevelopmental risk in children born to mothers living with HIV in Kenya
$649,747Megan Song McHenry · Indiana University Indianapolis · R01 · FY2025 · HD
The effect of inflammation and damage to lymph node structures on durable protective immunity following vaccination
$649,719Timothy W Schacker · University Of Minnesota · U01 · FY2023 · AI
Relapsing malaria in Africa: mechanisms for persistence amid falciparum decline
$649,572Jonathan J Juliano · Univ Of North Carolina Chapel Hill · R01 · FY2023 · AI
Coping With HIV/AIDS in Tanzania
$649,145Kathryn Whetten · Duke University · R01 · FY2007 · MH
Lead optimization and target identification of drugs targeting hypnozoites
$649,072Dennis E Kyle · University Of Georgia · R01 · FY2024 · AI
Defining the complex genetic basis of Plasmodium falciparum resistance to artemisinin and quinine and identifying resistance-refractory therapeutics
$648,982David Armand Fidock · Columbia University Health Sciences · R01 · FY2025 · AI
Synthesis of Anti-Infective Agents
$648,931K. C. Nicolaou · Scripps Research Institute, The · R01 · FY2011 · AI
Mosquito extracellular vesicles in malaria parasite killing and immune priming
$648,924Ryan C. Smith · Iowa State University · R01 · FY2025 · AI
Defining the complex genetic basis of Plasmodium falciparum resistance to artemisinin and quinine and identifying resistance-refractory therapeutics
$648,448David Armand Fidock · Columbia University Health Sciences · R01 · FY2024 · AI